title: The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine.
abstract: OBJECTIVE
  To investigate the effects of brachytherapy with computed tomography-guided percutaneous radioactive I-125 seeds interstitial implantation (ISI) synchronized chemotherapy and Chinese medicine (CM) for the treatment of advanced stage of non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Ninety patients diagnosed with NSCLC by biopsy were randomly assigned to three groups: the synchronized therapy group (A), the chemotherapy plus CM-treated group (B), and the chemotherapy-treated group (C); a 2-month course of treatment was administered to them all. The effectiveness of treatment was evaluated based on tumor size, tumor markers (carcinoembryonic, squamous cell carcinoma-associated antigen, and cytokeratin 19 fragment), clinical symptoms, and quality of life (QOL) in patients.
  
  
  RESULTS
  The total effective rates of Groups A to C were 83.33%, 46.67%, and 43.33%, respectively. The tumor markers were reduced obviously in Group A, showing signifificant difference compared with those in the other two groups. Additionally, QOL was elevated and cancer-related symptoms were alleviated more signifificant in Group A than those in Group C (all P<0.05).
  
  
  CONCLUSIONS
  The synchronized therapy of I-125 implantation with chemotherapy and CM was a safe therapeutic method and can be regarded as a new mode for treatment of advanced-stage NSCLC.
authors.affiliation: Department of Traditional Chinese Medicine, Chinese People's Liberation Army General Hospital, Beijing, China. fengwengang5097@sina.com
authors.forename: Yu
authors.initials: Y
authors.lastname: Feng
authors.forename: Yue-Yong
authors.initials: YY
authors.lastname: Xiao
authors.forename: Shao-Dan
authors.initials: SD
authors.lastname: Li
authors.forename: Ming-Xiong
authors.initials: MX
authors.lastname: Lin
authors.forename: Yin
authors.initials: Y
authors.lastname: Zhang
authors.forename: Hai-Ming
authors.initials: HM
authors.lastname: Wang
authors.forename: Min
authors.initials: M
authors.lastname: Li
authors.forename: Xiao
authors.initials: X
authors.lastname: Zhang
authors.forename: Ke
authors.initials: K
authors.lastname: Cao
authors.forename: Yu-Fei
authors.initials: YF
authors.lastname: Ye
authors.forename: Li
authors.initials: L
authors.lastname: Zhao
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D001918:Brachytherapy / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004365:Drugs, Chinese Herbal; D007457:Iodine Radioisotopes